Abstract 96P
Background
Archival storage of blood for single-cell (sc) RNA-Seq involves cryopreservation of peripheral blood mononuclear cells (PBMCs). However, this method excludes granulocytes and requires isolation of viable cells, whose transcriptomes may change due to processing time and technician handling. Hence, this method might overlook important data from temporal collection of clinical specimens. By contrast, blood collection in Qiagen PAXgene Blood RNA tubes is routinely practiced in medical sites without any special processing, and is completed with highly stabilized transcriptomes. Here, we present a novel method for single-nucleus (sn) RNA-Seq nuclei from frozen PAXgene blood as an alternative to PBMCs.
Methods
Fresh blood from healthy donors was collected, frozen in PAXgene tubes and processed by our novel method, which utilizes single-nucleus isolation and CRISPR-based strategy, yielding 3’RNA-Seq data via 10x Genomics’ Chromium platform. PBMCs from the same bloods were processed in parallel.
Results
Data quality evaluation revealed that PBMC transcript detection was higher than PAXgene, yet PAXgene RNA quality might exceed that of PBMCs. Unsupervised clustering was used to define cells and marker gene detection was used to assign cell types in PBMC and PAXgene data. Cell type subpopulations could be identified in PAXgene data, including central- and effector memory cells, and CD14+/16+ monocytes. Importantly, cells clustered based on cell type, indicating that sample biology was not masked by collection method. However, PAXgene specimens were distinct due to robust detection of granulocytes, including neutrophils (30-50% of blood cells). Proportions of PAXgene mononuclear cell populations were not significantly different from donor matched PBMCs. Results indicate that frozen PAXgene blood can be used to generate snRNA-Seq data that is comparable to PBMC scRNA-Seq, while also enabling transcriptomic characterization of granulocytes.
Conclusions
These findings provide preliminary evidence that PAXgene blood collection represents a simple, stable alternative to PBMC cryopreservation that could facilitate high quality, reproducible single-cell genomic profiling in clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AsatraZeneca.
Disclosure
A. Rotem, O. Chaudhary, G. Duclos, P. Gathungu, M. Rao, R. Aguilar, L. Amir-Zilberstein, V. Shankarappa, C. Rands, X. Chen, E. Galery Harbolick, R. Halpin, M. Steinberg, J. Boland, M. Scaltriti, B. Dougherty: Financial Interests, Full or part-time Employment: AstraZeneca.
Resources from the same session
41P - Cancer therapy-related cardiac dysfunction (CTRCD) after radiation therapy for breast cancer: Results of the French BACCARAT study
Presenter: Manoj Kumar Francois HONARYAR
Session: Poster session 07
Resources:
Abstract
42P - Correlation of circulating tumor cells with cancer stage
Presenter: Ana Paz
Session: Poster session 07
43P - A redesigned cell atlas of colon cancers to better assess their cellular composition
Presenter: Marine Sroussi
Session: Poster session 07
76P - Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
Presenter: Richard Tothill
Session: Poster session 07
77P - Whole-exome mutation profiling of cfDNA from over 2000 samples in major cancer indications
Presenter: Eric Jia
Session: Poster session 07
78P - Real-world analysis of actionable gene fusions identified by NGS and correlation with IHC in 422 patients from the community
Presenter: Husain Hatim
Session: Poster session 07
79P - Comprehensive genomic profiling provides patients access to novel matched therapies in a diverse real-world cohort of advanced lung cancer patients
Presenter: Jyoti Patel
Session: Poster session 07
80P - Development of a next-generation sequencing diagnostics recommender tool in the framework of the molecular tumor board Freiburg
Presenter: Ralf Mertes
Session: Poster session 07
81P - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs – Preliminary data after two years of enrollment
Presenter: Katriina Jalkanen
Session: Poster session 07
82P - Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE: The national phase II drug repurposing trial in Finland
Presenter: Anniina Färkkilä
Session: Poster session 07